Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer Nails Down Deal To Share Ex-U.S. Rights For Wet AMD Treatment

This article was originally published in The Pink Sheet Daily

Executive Summary

Agreement with Regeneron includes joint development and commercialization of VEGF-Trap Eye for wet AMD and diabetic macular edema.

You may also be interested in...



Alcon Grabs Ex-U.S. Rights To ThromboGenics' Retina Adhesion Therapy Ocriplasmin In $500 Mil. Deal

Novartis' ophthalmic unit Alcon will collaborate with Belgium's ThromboGenics on the marketing and future development of the vitreomacular adhesion therapy, ocriplasmin.

Bayer/Regeneron Phase III Will Study Eight-Week Dosing With VEGF Trap-Eye

Non-inferiority trial will compare the VEGF Trap-Eye candidate to Genentech’s Lucentis.

Bayer/Regeneron Phase III Will Study Eight-Week Dosing With VEGF Trap-Eye

Non-inferiority trial will compare the VEGF Trap-Eye candidate to Genentech’s Lucentis.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel